New treatment regimen extends life for some men with recurrent prostate cancer, study finds

February 1, 2017, Cedars-Sinai Medical Center
"Our study indicates that hormonal treatments should be incorporated into the management of men who need radiation therapy after surgery for prostate cancer," said Howard Sandler, MD, chair of the Department of Radiation Oncology the Samuel Oschin Comprehensive Cancer Institute at Cedar's Sinai and senior author of the multicenter study. Credit: Cedars-Sinai

Adding hormonal therapy to radiation treatment can significantly improve the average long-term survival of men with prostate cancer who have had their prostate gland removed, according to a new Cedars-Sinai study published in the Feb. 2 issue of the New England Journal of Medicine. The regimen also can reduce the frequency of spread of the cancer, the study found.

Prostate cancer is the second most common cancer in U.S. men. An estimated 161,300 new cases will be diagnosed and nearly 27,000 deaths are expected in 2017, according to the American Cancer Society.

"Our study indicates that hormonal treatments should be incorporated into the management of men who need radiation therapy after surgery for ," said Howard Sandler, MD, chair of the Department of Radiation Oncology the Samuel Oschin Comprehensive Cancer Institute at Cedar's Sinai and senior author of the multicenter study.

More than 30 percent of prostate cancer patients face the return of disease one to four years after removal of the , Sandler said.

When a patient experiences a recurrence, physicians typically prescribe radiation therapy. "Our results show that adding hormone therapy could add years to patients' lives," Sandler said.

The study, which included researchers at 17 medical institutions, tracked 761 prostate cancer patients in the U.S. and Canada during a 12-year period after they had participated in a randomized clinical trial of the combined treatment, from 1998 to 2003.

The study's findings include:

  • After 12 years, the incidence of deaths from prostate cancer was 5.4 percent for patients who underwent radiation therapy plus hormone treatment, compared with 13.4 percent for those who had only radiation therapy.
  • The incidence of prostate cancer metastasis was 14.5 percent for patients who received both treatments, compared with 23 percent for those who had only .
  • Side effects were low and similar in both groups of patients.

The hormonal treatment used in the study was designed to suppress male hormones, known as androgens, which can stimulate growth of . Randomized study participants took the drug daily for two years. The specific drug they received, bicalutamide, has since been supplanted by another drug, GnRH agonists, in clinical practice, Sandler said. But because both drugs suppress hormone production, he said the study presents "proof of principle" that combining with significantly reduces the rate of metastases and death in the patient group studied.

"This important research addressed a significant question in the care of patients with prostate cancer, showing the continued advancement in extending a good quality of life to those patients," said Steven Piantadosi, MD, PhD, director of the Samuel Oschin Comprehensive Cancer Institute. "Dr. Sandler's leadership demonstrates how Cedars-Sinai is contributing significantly to improving the outcomes of patients with cancer."

Sandler said that future studies will explore whether all or only some prostate cancer patients need , the duration of treatment and the role of more powerful hormone therapies.

Explore further: Markers for prostate cancer death can identify men in need of more aggressive treatment

More information: New England Journal of Medicine, dx.doi.org/10.1056/NEJMoa1607529

Related Stories

Markers for prostate cancer death can identify men in need of more aggressive treatment

January 12, 2017
Prostate cancer (PC) is the second leading cause of male cancer death in the United States with an estimated 26,000 deaths in 2016. Two-thirds of all PC deaths observed in the US are men with localized disease who developed ...

Cardiac risk a factor when considering hormonal therapy for prostate cancer

September 28, 2016
In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack. The findings were presented September 28 at ...

Shortened radiation therapy offers similar quality of life for low-risk prostate cancer patients

September 26, 2016
Low-risk prostate cancer patients may be able to undergo a shortened course of radiation therapy that cuts treatment by weeks and offers comparable outcomes and quality of life results as those who undergo longer treatment ...

High-dose radiation therapy as effective as surgery for aggressive prostate cancer

August 8, 2016
A study by researchers at the UCLA Jonsson Comprehensive Cancer Center provides convincing evidence that radiation-based treatments and surgery are equally effective treatments for aggressive prostate cancer. It also suggests ...

Radiation plus hormone therapy prolongs survival for older men with prostate cancer

January 5, 2015
Adding radiation treatment to hormone therapy saves more lives among older men with locally advanced prostate therapy than hormone therapy alone, according to a new study in the Journal of Clinical Oncology this week from ...

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.